## Yazhuo Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4928568/publications.pdf

Version: 2024-02-01

118 papers 3,589 citations

304743 22 h-index 54 g-index

125 all docs 125 docs citations

125 times ranked

4694 citing authors

#	Article	IF	CITATIONS
1	Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence. Neurosurgical Review, 2022, 45, 1451-1462.	2.4	13
2	Reduced sensitivity to delayed time and delayed reward of the post-operative insular glioma patients in delay discounting. NeuroImage: Clinical, 2022, 33, 102895.	2.7	O
3	The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1. Journal of Experimental and Clinical Cancer Research, 2022, 41, 26.	8.6	11
4	The clinical application of intraoperative visual evoked potential in recurrent craniopharyngiomas resected by extended endoscopic endonasal surgery. Clinical Neurology and Neurosurgery, 2022, 214, 107149.	1.4	1
5	Feasibility of endoscopic endonasal resection of intrinsic third ventricular craniopharyngioma in adults. Neurosurgical Review, 2022, 45, 1-13.	2.4	7
6	LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis. Cancer Cell International, 2021, 21, 14.	4.1	11
7	Phosphorylation of Pit-1 by cyclin-dependent kinase 5 at serine 126 is associated with cell proliferation and poor prognosis in prolactinomas. Open Chemistry, 2021, 19, 785-793.	1.9	0
8	Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas. Cell Biology and Toxicology, 2021, 37, 633-651.	<b>5.</b> 3	20
9	A nomogram to predict the progression-free survival of clival chordoma. Journal of Neurosurgery, 2021, 134, 144-152.	1.6	11
10	Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nature Communications, 2021, 12, 757.	12.8	55
11	The Functional Reorganization of Language Network Modules in Glioma Patients: New Insights From Resting State fMRI Study. Frontiers in Oncology, 2021, 11, 617179.	2.8	8
12	The clinical features, recurrence risks and surgical strategies of bone invasive pituitary adenomas. Clinical Neurology and Neurosurgery, 2021, 201, 106455.	1.4	3
13	Clinical Implication of Systemic Immune-Inflammation Index and Prognostic Nutritional Index in Skull Base Chordoma Patients. Frontiers in Oncology, 2021, 11, 548325.	2.8	5
14	Identifying critical protein‑coding genes and long non‑coding RNAs in non‑functioning pituitary adenoma recurrence. Oncology Letters, 2021, 21, 264.	1.8	8
15	Predicting the location of the preoptic and anterior hypothalamic region by visualizing the thermoregulatory center on fMRI in craniopharyngioma using cold and warm stimuli. Aging, 2021, 13, 10087-10098.	3.1	3
16	In Vivo Characterization of Cortical and White Matter Microstructural Pathology in Growth Hormone-Secreting Pituitary Adenoma. Frontiers in Oncology, 2021, 11, 641359.	2.8	2
17	Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma. Frontiers in Genetics, 2021, 12, 627117.	2.3	6
18	High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in Glioma. Frontiers in Oncology, 2021, 11, 650534.	2.8	15

#	Article	IF	CITATIONS
19	Endoscopic Endonasal Surgical Strategy for Skull Base Chordomas Based on Tumor Growth Directions: Surgical Outcomes of 167 Patients During 3 Years. Frontiers in Oncology, 2021, 11, 724972.	2.8	6
20	Proteomics Analysis Identified ASNS as a Novel Biomarker for Predicting Recurrence of Skull Base Chordoma. Frontiers in Oncology, 2021, 11, 698497.	2.8	9
21	Expression of Transforming Growth Factor $\hat{l}^2l$ , Smad3, and Phospho-Smad3 in Somatotropinomas and Their Relationship to Tumor Behavior. World Neurosurgery, 2021, 153, e20-e27.	1.3	4
22	Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5. Cell Proliferation, 2021, 54, e13136.	5.3	9
23	Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype. Aging, 2021, 13, 1276-1293.	3.1	7
24	Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors. Aging, 2021, 13, 1422-1439.	3.1	2
25	Prognostic Utility of Optical Coherence Tomography for Visual Outcome After Extended Endoscopic Endonasal Surgery for Adult Craniopharyngiomas. Frontiers in Oncology, 2021, 11, 764582.	2.8	1
26	MicroRNA-146b-5p/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4/TRAF6/NF-κB signaling pathway in aggressive pituitary adenoma. Histology and Histopathology, 2021, , 18391.	0.7	5
27	High Red Cell Distribution Width Independently Predicts Adverse Survival in Patients with Newly Diagnosed Skull Base Chordoma. OncoTargets and Therapy, 2021, Volume 14, 5435-5445.	2.0	2
28	Expanded Transsphenoidal Trans-Lamina Terminalis Approach to Tumors Extending Into the Third Ventricle: Technique Notes and a Single Institute Experience. Frontiers in Oncology, 2021, 11, 761281.	2.8	8
29	A modified endovascular treatment protocol for iatrogenic internal carotid artery injuries following endoscopic endonasal surgery. Journal of Neurosurgery, 2020, 132, 343-350.	1.6	31
30	Brain Morphometric and Functional Magnetic Resonance Imaging Study on Patients with Visual Field Defects Resulting from Suprasellar Tumors: Preoperative and Postoperative Assessment. World Neurosurgery, 2020, 134, e353-e359.	1.3	5
31	Metabolic profiling of acromegaly using a GC–MS-based nontargeted metabolomic approach. Endocrine, 2020, 67, 433-441.	2.3	10
32	Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study. BMC Cancer, 2020, 20, 988.	2.6	11
33	Contrahemispheric Cortex Predicts Survival and Molecular Markers in Patients With Unilateral High-Grade Gliomas. Frontiers in Oncology, 2020, 10, 953.	2.8	1
34	<p>Prognostic Value of Cumulative Score Based on Preoperative Fibrinogen and Albumin Level in Skull Base Chordoma</p> . OncoTargets and Therapy, 2020, Volume 13, 8337-8346.	2.0	9
35	JAG1, Regulated by microRNA-424-3p, Involved in Tumorigenesis and Epithelial–Mesenchymal Transition of High Proliferative Potential-Pituitary Adenomas. Frontiers in Oncology, 2020, 10, 567021.	2.8	9
36	Somatic SF3B1 hotspot mutation in prolactinomas. Nature Communications, 2020, 11, 2506.	12.8	38

#	Article	IF	Citations
37	Application of endoscopic endonasal approach in skull base surgeries: summary of 1886 cases in a single center for 10 consecutive years. Chinese Neurosurgical Journal, 2020, 6, 21.	0.9	4
38	Transcortical approach for insular gliomas: a series of 253 patients. Journal of Neuro-Oncology, 2020, 147, 59-66.	2.9	12
39	The role of serum growth hormone and insulin-like growth factor-1 in adult humans brain morphology. Aging, 2020, 12, 1377-1396.	3.1	8
40	Structural plasticity of the bilateral hippocampus in glioma patients. Aging, 2020, 12, 10259-10274.	3.1	8
41	LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma. Aging, 2020, 12, 10809-10826.	3.1	3
42	CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas. International Journal of Molecular Medicine, 2020, 47, 500-510.	4.0	5
43	Clinical and Radiologic Characteristics, Surgical Outcomes, and Its Possible Origins of Chondroma of the Dural Convexity. BioMed Research International, 2020, 2020, 1-10.	1.9	2
44	A Series of 62 Skull Base Chordomas in Pediatric and Adolescent Patients: Clinical Characteristics, Treatments, and Outcomes. Neurology India, 2020, 68, 1030.	0.4	5
45	Identification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas. International Journal of Endocrinology, 2019, 2019, 1-12.	1.5	30
46	Predictive Value of Transforming Growth Factor- $\hat{l}_{\pm}$ and Ki-67 for the Prognosis of Skull Base Chordoma. World Neurosurgery, 2019, 129, e199-e206.	1.3	8
47	CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial–mesenchymal transition. Journal of Translational Medicine, 2019, 17, 336.	4.4	16
48	The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma. Journal of Translational Medicine, 2019, 17, 354.	4.4	10
49	The Apoptosis Regulator 14-3-3î· and Its Potential as a Therapeutic Target in Pituitary Oncocytoma. Frontiers in Endocrinology, 2019, 10, 797.	3.5	10
50	Identification of a novel somatic mutation of <i>POU6F2</i> by wholeâ€genome sequencing in prolactinoma. Molecular Genetics & Enomic Medicine, 2019, 7, e1022.	1.2	12
51	Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets. Journal of Translational Medicine, 2019, 17, 291.	4.4	9
52	DAPT, a $\hat{I}^3$ -Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling. Frontiers in Oncology, 2019, 9, 809.	2.8	31
53	Impact of SLC20A1 on the Wnt/l²â€'catenin signaling pathway in somatotroph adenomas. Molecular Medicine Reports, 2019, 20, 3276-3284.	2.4	8
54	Comparative evaluation of neuroendocrine dysfunction in children with craniopharyngiomas before and after mass effects are removed. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 127-133.	0.9	8

#	Article	IF	CITATIONS
55	Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas. International Journal of Endocrinology, 2019, 2019, 1-8.	1.5	7
56	Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model. Journal of Translational Medicine, 2019, 17, 164.	4.4	9
57	Long-Term Follow-Up Studies of Gamma Knife Radiosurgery for Postsurgical Nonfunctioning Pituitary Adenomas. World Neurosurgery, 2019, 124, e715-e723.	1.3	14
58	Increased resting-state functional connectivity in suprasellar tumor patients with postoperative visual improvement. International Journal of Medical Sciences, 2019, 16, 1245-1253.	2.5	4
59	Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. Journal of Translational Medicine, 2019, 17, 407.	4.4	18
60	Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review. World Neurosurgery, 2019, 122, e978-e988.	1.3	7
61	Expression of Cyclin E/Cdk2/p27Kip1 in Growth Hormone Adenomas. World Neurosurgery, 2019, 121, e45-e53.	1.3	7
62	Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis. Open Chemistry, 2019, 17, 1501-1508.	1.9	0
63	Attenuation of EGFL7 Expression Inhibits Growth Hormone–Producing Pituitary Adenomas Growth and Invasion. Human Gene Therapy, 2018, 29, 1396-1406.	2.7	6
64	Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas. World Neurosurgery, 2018, 115, e146-e151.	1.3	7
65	P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma. Journal of Neuro-Oncology, 2018, 136, 485-494.	2.9	4
66	Analysis of clinical factors and PDGFR- $\hat{l}^2$ in predicting prognosis of patients with clival chordoma. Journal of Neurosurgery, 2018, 129, 1429-1437.	1.6	19
67	Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14â€3â€3η in oncocytomas. Journal of Pathology, 2018, 245, 361-372.	4.5	17
68	Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery. European Radiology, 2018, 28, 3692-3701.	4.5	58
69	Application of endoscopic third ventriculostomy for treating hydrocephalus-correlated Chiari type I malformation in a single Chinese neurosurgery centre. Neurosurgical Review, 2018, 41, 249-254.	2.4	17
70	A deep learning model integrating FCNNs and CRFs for brain tumor segmentation. Medical Image Analysis, 2018, 43, 98-111.	11.6	568
71	SNF5 as a prognostic factor in skull base chordoma. Journal of Neuro-Oncology, 2018, 137, 139-146.	2.9	14
72	Epithelial–Mesenchymal Transition Induced by SMAD4 Activation in Invasive Growth Hormone-Secreting Adenomas. Open Chemistry, 2018, 16, 571-582.	1.9	3

#	Article	IF	CITATIONS
73	Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion. Open Chemistry, 2018, 16, 621-626.	1.9	1
74	Integration of Proteomics and Metabolomics Revealed Metabolite–Protein Networks in ACTH-Secreting Pituitary Adenoma. Frontiers in Endocrinology, 2018, 9, 678.	3.5	25
75	A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncology Reports, 2018, 41, 113-124.	2.6	9
76	Association of TGF-Î <sup>2</sup> 1 and WIF1 Expression with 36 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas: A High-Throughput Tissue Microarrays Immunohistochemical Study. World Neurosurgery, 2018, 119, e23-e31.	1.3	4
77	Neuro-endoscope for skull base tumors. Clinical Neurology and Neurosurgery, 2018, 170, 102-105.	1.4	7
78	Role of EGFL7/EGFR-signaling pathway in migration and invasion of growth hormone-producing pituitary adenomas. Science China Life Sciences, 2018, 61, 893-901.	4.9	16
79	Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas. Clinical Cancer Research, 2018, 24, 5757-5766.	7.0	43
80	Mixed gangliocytoma-pituitary adenoma in the sellar region: a large-scale single-center experience. Acta Neurochirurgica, 2018, 160, 1989-1999.	1.7	13
81	Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. Journal of Neuro-Oncology, 2017, 132, 199-206.	2.9	18
82	In Reply to "Prognostic Significance of Resection Degree inÂSkull Base Chordoma: A Systematic Review and Meta-Analysis〕 World Neurosurgery, 2017, 100, 695.	1.3	0
83	In Reply to "Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature― World Neurosurgery, 2017, 101, 785.	1.3	0
84	Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes. Oncology Letters, 2017, 13, 4533-4539.	1.8	3
85	Upregulation of cyclin B1 plays potential roles in the invasiveness of pituitary adenomas. Journal of Clinical Neuroscience, 2017, 43, 267-273.	1.5	20
86	Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas. World Neurosurgery, 2017, 99, 282-287.	1.3	4
87	ESR1 and its antagonist fulvestrant in pituitary adenomas. Molecular and Cellular Endocrinology, 2017, 443, 32-41.	3.2	23
88	Prevalence, Incidence, and Mortality of Stroke in China. Circulation, 2017, 135, 759-771.	1.6	1,450
89	Alterations of regional homogeneity and functional connectivity in pituitary adenoma patients with visual impairment. Scientific Reports, 2017, 7, 13074.	3.3	12
90	Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncology Reports, 2017, 38, 1140-1148.	2.6	30

#	Article	IF	Citations
91	EGFL7 participates in regulating biological behavior of growth hormone–secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumor Biology, 2017, 39, 101042831770620.	1.8	32
92	Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell. Cancer Cell International, 2017, 17, 15.	4.1	13
93	Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β. World Neurosurgery, 2017, 98, 288-295.	1.3	21
94	Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas. World Neurosurgery, 2017, 98, 323-328.	1.3	17
95	Increased $\hat{I}^2$ -catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach. Molecular Medicine Reports, 2017, 15, 1793-1799.	2.4	13
96	Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq. Oncotarget, 2017, 8, 4595-4606.	1.8	23
97	Smad3 and phospho-Smad3 are potential markers of invasive nonfunctioning pituitary adenomas. OncoTargets and Therapy, 2016, 9, 2265.	2.0	13
98	Use of micro-positron emission tomography with 18F-fallypride to measure the levels of dopamine receptor-D2 and 18F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats. OncoTargets and Therapy, 2016, 9, 2057.	2.0	2
99	Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas. Oncology Reports, 2016, 35, 2991-2999.	2.6	3
100	Intraoperative Hemorrhage in Ventriculoscopic Surgery: Experience of a Single Chinese Neurosurgery Center. World Neurosurgery, 2016, 88, 548-551.	1.3	7
101	Whole-exome sequencing identifies variants in invasive pituitary adenomas. Oncology Letters, 2016, 12, 2319-2328.	1.8	26
102	Solitary subdural osteoma: A case report and literature review. Oncology Letters, 2016, 12, 1023-1026.	1.8	7
103	The role of FSCN1 in migration and invasion of pituitary adenomas. Molecular and Cellular Endocrinology, 2016, 419, 217-224.	3.2	40
104	Pressure balance and imbalance in the optic nerve chamber: The Beijing Intracranial and Intraocular Pressure (iCOP) Study. Science China Life Sciences, 2016, 59, 495-503.	4.9	24
105	Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases. Neurosurgical Review, 2016, 39, 321-333.	2.4	43
106	Low expression of secreted frizzled-related protein 2 and nuclear accumulation of $\hat{l}^2$ -catenin in aggressive nonfunctioning pituitary adenoma. Oncology Letters, 2016, 12, 199-206.	1.8	17
107	Intracranial pressure (ICP) and optic nerve subarachnoid space pressure (ONSP) correlation in the optic nerve chamber: the Beijing Intracranial and Intraocular Pressure (iCOP) study. Brain Research, 2016, 1635, 201-208.	2.2	56
108	Surgical outcome of encapsulated brain abscess in superficial non-eloquent area: A systematic review. British Journal of Neurosurgery, 2016, 30, 29-34.	0.8	18

#	Article	IF	CITATIONS
109	Assessment of endoscopic treatment for quadrigeminal cistern arachnoid cysts: A 7-year experience with 28 cases. Child's Nervous System, 2016, 32, 647-654.	1.1	21
110	Potassium Aspartate Attenuates Brain Injury Induced by Controlled Cortical Impact in Rats Through Increasing Adenosine Triphosphate (ATP) Levels, Na+/K+-ATPase Activity and Reducing Brain Edema. Medical Science Monitor, 2016, 22, 4894-4901.	1.1	6
111	Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas. Oncotarget, 2016, 7, 50883-50894.	1.8	16
112	Surgical resection of unilateral thalamic tumors in adults: approaches and outcomes. BMC Neurology, 2015, 15, 229.	1.8	32
113	Identification of Differentially Expressed Genes in Pituitary Adenomas by Integrating Analysis of Microarray Data. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	19
114	The role of TGF- $\hat{l}^2$ /Smad signaling in dopamine agonist-resistant prolactinomas. Molecular and Cellular Endocrinology, 2015, 402, 64-71.	3.2	34
115	Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer, 2015, 15, 272.	2.6	34
116	Overexpression of the cell adhesion molecule claudin-9 is associated with invasion in pituitary oncocytomas. Human Pathology, 2014, 45, 2423-2429.	2.0	18
117	Effects of fulvestrant on biological activity and Wnt expression in rat GH3 cells. Neural Regeneration Research, 2012, 7, 283-9.	3.0	1
118	Endoscopic transsphenoidal treatment of pituitary adenomas. Neurological Research, 2008, 30, 581-586.	1.3	38